National Taxpayers Union Backs S.1414, Opposes $35 Insulin Cap and S.5026 Food Label Bill
Updated
Updated · National Taxpayers Union · Jul 22
National Taxpayers Union Backs S.1414, Opposes $35 Insulin Cap and S.5026 Food Label Bill
1 articles · Updated · National Taxpayers Union · Jul 22
Summary
National Taxpayers Union told the Senate HELP Committee it supports S.1414, the Expedited Access to Biosimilars Act, while opposing the INSULIN Act of 2026 and the Childhood Diabetes Reduction Act.
S.1414 would streamline FDA approval for biosimilars, which NTU said would cut costly clinical requirements, boost competition and lower prices in taxpayer-funded health programs.
The group argued S.4189’s $35 monthly insulin cap for privately insured patients would shift costs to insurers and likely raise premiums rather than reduce underlying drug costs.
NTU also said S.5026’s proposed warning labels and child-directed advertising limits on certain foods would duplicate existing FDA rules, raise compliance costs and give HHS broad discretion over "ultra-processed" foods.
The recommendations were submitted ahead of the committee’s July 22 markup of a broader health package, framing NTU’s stance around taxpayer protection and free-market principles.